# Study to Investigate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Single & Repeat Doses of GSK2269557

> **NCT01462617** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 61 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** GSK2269557
- **DRUG:** GSK2269557 matching placebo

## Key facts

- **NCT ID:** NCT01462617
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07-24
- **Primary completion:** 2012-03-26
- **Final completion:** 2012-03-26
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2017-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01462617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01462617, "Study to Investigate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Single & Repeat Doses of GSK2269557". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01462617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*